Adenosine receptors as drug targets-what are the challenges?

Nature Reviews Drug Discovery

Volumn 12, Issue 4, 2013, Pages 265-286

  Chen, Jiang Fan ^a   Eltzschig, Holger K ^b   Fredholm, Bertil B ^c  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

6 N (3 IODOBENZYL)ADENOSINE 5' N METHYLCARBOXAMIDE; ADENOSINE; ADENOSINE A1 RECEPTOR; ADENOSINE A1 RECEPTOR AGONIST; ADENOSINE A2A RECEPTOR; ADENOSINE A2B RECEPTOR; ADENOSINE A3 RECEPTOR; ADENOSINE A3 RECEPTOR AGONIST; ADENOSINE RECEPTOR; APADENOSON; CAFFEINE; CF 102; DIPYRIDAMOLE; GW 493838; INO 8875; ISTRADEFYLLINE; LEVODOPA; PLACEBO; PREDNISOLONE; PRELADENANT; REGADENOSON; ROLOFYLLINE; TONAPOFYLLINE; TOZADENANT; UNCLASSIFIED DRUG;

ACUTE HEART FAILURE; ALLOSTERISM; ARTICLE; AUTOIMMUNE DISEASE; BRAIN ISCHEMIA; COCAINE DEPENDENCE; CORONARY ARTERY BYPASS SURGERY; CORONARY ARTERY DISEASE; DAYTIME SOMNOLENCE; DIMERIZATION; DISEASE COURSE; DRUG STRUCTURE; DRUG TARGETING; DRY EYE; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GLAUCOMA; HEART FAILURE; HEPATITIS; HUMAN; INFLAMMATORY DISEASE; INTRAOCULAR HYPERTENSION; KIDNEY FAILURE; LIVER CANCER; LIVER CELL CARCINOMA; MELANOMA; MOTOR DYSFUNCTION; MYOCARDIAL PERFUSION IMAGING; NEUROPATHIC PAIN; NEWBORN APNEA; NONHUMAN; PARKINSON DISEASE; PATHOPHYSIOLOGY; PERIPHERAL NERVE INJURY; POSTHERPETIC NEURALGIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PSORIASIS; PSORIASIS VULGARIS; RHEUMATOID ARTHRITIS; SICKLE CELL ANEMIA; SIGNAL TRANSDUCTION; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TISSUE DISTRIBUTION; TISSUE SPECIFICITY;

ADENOSINE A2 RECEPTOR AGONISTS; ANIMALS; DRUG APPROVAL; DRUG DESIGN; HUMANS; MOLECULAR TARGETED THERAPY; PURINES; PYRAZOLES; RECEPTORS, PURINERGIC P1; SIGNAL TRANSDUCTION; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84875700546     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd3955     Document Type: Article

References (297)

1. Fredholm, B. B. et al. International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol. Rev. 53, 527-552 (2001).
2. Fredholm, B. B. et al. International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and classification of adenosine receptors - an update. Pharmacol. Rev. 63, 1-34 (2011).
3. Eltzschig, H. K., Sitkovsky, M. V. & Robson, S. C. Purinergic signaling during inflammation. N. Engl. J. Med. 367, 2322-2333 (2012).
4. Eltzschig, H. K. Adenosine: an old drug newly discovered. Anesthesiology 111, 904-915 (2009).
5. 2 and nicotinic acid. Acta Physiol. 190, 87-96 (2007).
6. Grenz, A. et al. Equilibrative nucleoside transporter 1 (ENT1) regulates postischemic blood flow during acute kidney injury in mice. J. Clin. Invest. 122, 693-710 (2012).
7. Sun, D. et al. Mediation of tubuloglomerular feedback by adenosine: evidence from mice lacking adenosine 1 receptors. Proc. Natl Acad. Sci. USA 98, 9983-9988 (2001).
8. Rosenberger, P. et al. Hypoxia-inducible factor-dependent induction of netrin-1 dampens inflammation caused by hypoxia. Nature Immunol. 10, 195-202 (2009).
9. 1, receptors mediate the arousal effect of caffeine. Nature Neurosci. 8, 858-859 (2005).
10. Lazarus, M. et al. Arousal effect of caffeine depends on adenosine A2A receptors in the shell of the nucleus accumbens. J. Neurosci. 31, 10067-10075 (2011).
11. Liu, X. L. et al. Genetic inactivation of the adenosine A2A receptor attenuates pathologic but not developmental angiogenesis in the mouse retina. Invest. Ophthalmol. Vis. Sci. 51, 6625-6632 (2010).
12. Hasko, G., Linden, J., Cronstein, B. & Pacher, P. Adenosine receptors: therapeutic aspects for inflammatory and immune diseases. Nature Rev. Drug Discov. 7, 759-770 (2008).
13. Eltzschig, H. K. & Carmeliet, P. Hypoxia and inflammation. N. Engl. J. Med. 364, 656-665 (2011).
14. Eltzschig, H. K. & Eckle, T. Ischemia and reperfusion - from mechanism to translation. Nature Med. 17, 1391-1401 (2011).
15. Fredholm, B. B. Adenosine, an endogenous distress signal, modulates tissue damage and repair. Cell Death Differ. 14, 1315-1323 (2007).
16. Jacobson, K. A. & Gao, Z. G. Adenosine receptors as therapeutic targets. Nature Rev. Drug Discov. 5, 247-264 (2006).
17. Delacretaz, E. Clinical practice. Supraventricular tachycardia. N. Engl. J. Med. 354, 1039-1051 (2006).
18. Muller, C. E. & Jacobson, K. A. Recent developments in adenosine receptor ligands and their potential as novel drugs. Biochim. Biophys. Acta 1808, 1290-1308 (2011).
19. Ghimire, G., Hage, F. G., Heo, J. & Iskandrian, A. E. Regadenoson: a focused update. J. Nucl. Cardiol. 11 Dec 2012 (doi:10.1007/s12350-012-9661-3).
20. Fredholm, B., Chen, J.-F., Masino, S. A. & Vaugeois, J.-M. Actions of adeosine at its receptors in the CNS: insights from knckouts and drugs. Annu. Rev. Pharmacol. Toxicol. 45, 385-412 (2005).
21. Massie, B. M. et al. Rolofylline, an adenosine A1-receptor antagonist, in acute heart failure. N. Engl. J. Med. 363, 1419-1428 (2010).
22. 1-receptor antagonist, rolofylline, in patients with acute heart failure and renal impairment: findings from PROTECT. Drug Saf. 35, 233-244 (2012).
23. Fredholm, B. B. et al. Structure and function of adenosine receptors and their genes. Naunyn Schmiedebergs Arch. Pharmacol. 362, 364-374 (2000).
24. Daly, J. W. & Padgett, W. L. Agonist activity of 2-and 5'-substituted adenosine analogs and their N6-cycloalkyl derivatives at A1-and A2-adenosine receptors coupled to adenylate cyclase. Biochem. Pharmacol. 43, 1089-1093 (1992).
25. Koeppen, M., Eckle, T. & Eltzschig, H. K. Selective deletion of the A1 adenosine receptor abolishes heart-rate slowing effects of intravascular adenosine in vivo. PLoS ONE 4, e6784 (2009).
26. olf is necessary for coupling D1 and A2a receptors to adenylyl cyclase in the striatum. J. Neurochem. 76, 1585-1588 (2001).
27. olf in rat striatum. Mol. Pharmacol. 58, 771-777 (2000).
28. Schulte, G. & Fredholm, B. B. Signalling from adenosine receptors to mitogen-activated protein kinases. Cell. Signal. 15, 813-827 (2003).
29. 2B adenosine receptor dampens hypoxia-induced vascular leak. Blood 111, 2024-2035 (2008).
30. Eckle, T. et al. Adora2b-elicited Per2 stabilization promotes a HIF-dependent metabolic switch crucial for myocardial adaptation to ischemia. Nature Med. 18, 774-782 (2012).
31. 2B adenosine receptor. J. Immunol. 186, 4367-4374 (2011).
32. 2B adenosine receptor dampens endotoxin-induced acute lung injury. J. Immunol. 184, 5271-5279 (2010).
33. 2B receptors to inflammatory parameters of experimental colitis. J. Immunol. 182, 4957-4964 (2009).
34. 3 receptor. J. Immunol. 171, 338-345 (2003).
35. 3 adenosine receptor is over-expressed in rheumatoid arthritis, psoriasis and Crohn's disease. Cell. Immunol. 258, 115-122 (2009).
36. 3 adenosine receptors in human colorectal cancer is reflected in peripheral blood cells. Clin. Cancer Res. 10, 5895-5901 (2004).
37. 3 adenosine receptor agonists. Drug Discov. Today 17, 359-366 (2012).
38. King, A. E., Ackley, M. A., Cass, C. E., Young, J. D. & Baldwin, S. A. Nucleoside transporters: from scavengers to novel therapeutic targets. Trends Pharmacol. Sci. 27, 416-425 (2006).
39. MacDonald, P. E., Braun, M., Galvanovskis, J. & Rorsman, P. Release of small transmitters through kiss-and-run fusion pores in rat pancreatic ß cells. Cell Metab. 4, 283-290 (2006).
40. Zhang, Z. et al. Regulated ATP release from astrocytes through lysosome exocytosis. Nature Cell Biol. 9, 945-953 (2007).
41. Chekeni, F B. et al. Pannexin 1 channels mediate 'find-me' signal release and membrane permeability during apoptosis. Nature 467, 863-867 (2010).
42. Elliott, M. R. et al. Nucleotides released by apoptotic cells act as a find-me signal to promote phagocytic clearance. Nature 461, 282-286 (2009).
43. 2+ signals across the inner ear. Proc. Natl. Acad. Sci. USA 105, 18770-18775 (2008).
44. Kanneganti, T. D. et al. Pannexin-1-mediated recognition of bacterial molecules activates the cryopyrin inflammasome independent of Toll-like receptor signaling. Immunity 26, 433-443 (2007).
45. Faigle, M., Seessle, J., Zug, S., El Kasmi, K. C. & Eltzschig, H. K. ATP release from vascular endothelia occurs across Cx43 hemichannels and is attenuated during hypoxia. PLoS ONE 3, e2801 (2008).
46. Ballarin, M., Fredholm, B. B., Ambrosio, S. & Mahy, N. Extracellular levels of adenosine and its metabolites in the striatum of awake rats: inhibition of uptake and metabolism. Acta Physiol. Scand. 142, 97-103 (1991).
47. Wei, C. J., Li, W. & Chen, J. F Normal and abnormal functions of adenosine receptors in the central nervous system revealed by genetic knockout studies. Biochim. Biophys. Acta 1808, 1358-1379 (2011).
48. Fedele, D. E., Li, T., Lan, J. Q., Fredholm, B. B. & Boison, D. Adenosine A1 receptors are crucial in keeping an epileptic focus localized. Exp. Neurol 200, 184-190 (2006).
49. Gimenez-Llort, L. et al. Mice lacking the adenosine A receptor are anxious and aggressive, but are normal learners with reduced muscle strength and survival rate. Eur. J. Neurosci. 16, 547-550 (2002).
50. 2A receptors in Parkinson's disease. Trends Neurosci. 29, 647-654 (2006).
51. Ferre, S., Fredholm, B. B., Morelli, M., Popoli, P. & Fuxe, K. Adenosine-dopamine receptor-receptor interactions as an integrative mechanism in the basal ganglia. Trends Neurosci. 20, 482-487 (1997).
52. 2A receptor antagonists as new agents for the treatment of Parkinson's disease. Trends Pharmacol. Sci. 18, 338-344 (1997).
53. 2A receptors in striatal neurons enhances working memory and reversal learning. Learn. Mem. 18, 459-474 (2011).
54. 2A receptors. Brain Res. 1303, 74-83 (2009).
55. 2A adenosine receptors in the striatum selectively impairs habit formation. J. Neurosci. 29, 15100-15103 (2009).
56. Ledent, C. et al. Aggressiveness, hypoalgesia and high blood pressure in mice lacking the adenosine A2a receptor. Nature 388, 674-678 (1997).
57. 2A adenosine receptor deficiency attenuates brain injury induced by transient focal ischemia in mice. J. Neurosci. 19, 9192-9200 (1999).
58. 2A receptors contribute to l-3, 4-dihydroxyphenylalanine-induced dyskinesia in hemiparkinsonian mice. J. Neurosci. 26, 13548-13555 (2006).
59. Ohta, A. & Sitkovsky, M. Role of G-protein-coupled adenosine receptors in downregulation of inflammation and protection from tissue damage. Nature 414, 916-920 (2001).
60. 2A adenosine receptors on bone marrow-derived cells. J. Clin. Invest. 112, 883-891 (2003).
61. 2A receptors and brain injury: broad spectrum of neuroprotection, multifaceted actions and "fine tuning" modulation. Prog. Neurobiol. 83, 310-331 (2007).
62. 2A receptors in bone marrow cells reveals their significant contribution to the development of ischemic brain injury. Nature Med. 10, 1081-1087 (2004).
63. Huang, Z. L., Urade, Y. & Hayaishi, O. The role of adenosine in the regulation of sleep. Curr. Top. Med. Chem. 11, 1047-1057 (2011).
64. 2B adenosine receptor protects against inflammation and excessive vascular adhesion. J. Clin. Invest. 116, 1913-1923 (2006).
65. 2B adenosine receptors. Circulation 115, 1581-1590 (2007).
66. 3 receptors expressed in Chinese hamster ovary cells all mediate the phosphorylation of extracellular-regulated kinase 1/2. Mol. Pharmacol. 58, 477-482 (2000).
67. 2B adenosine receptor signaling provides potent protection during intestinal ischemia/reperfusion injury. J. Immunol. 182, 3965-3968 (2009).
68. 2B receptor. Transplantation 94, 894-902 (2012).
69. 2B adenosine receptor protects the kidney from ischemia. PLoS Med. 5, e137 (2008).
70. 2B adenosine receptor signaling attenuates acute lung injury by enhancing alveolar fluid clearance in mice. J. Clin. Invest. 118, 3301-3315 (2008).
71. Takedachi, M. et al. CD73-generated adenosine promotes osteoblast differentiation. J. Cell. Physiol. 227, 2622-2631 (2012).
72. 2B adenosine receptor promotes mesenchymal stem cell differentiation to osteoblasts and bone formation in vivo. J. Biol. Chem. 287, 15718-15727 (2012).
73. Johnston-Cox, H. et al. The A2b adenosine receptor modulates glucose homeostasis and obesity. PLoS ONE 7, e40584 (2012).
74. Koupenova, M. et al. A2b adenosine receptor regulates hyperlipidemia and atherosclerosis. Circulation 125, 354-363 (2012).
75. 2B receptor blockade slows growth of bladder and breast tumors. J. Immunol. 188, 198-205 (2012).
76. 2B adenosine receptor-mediated induction of IL-6 promotes CKD. J. Am. Soc. Nephrol. 22, 890-901 (2011).
77. 2B adenosine receptor alleviates pathogenesis of experimental autoimmune encephalomyelitis via inhibition of IL-6 production and Th17 differentiation. J. Immunol. 190, 138-146 (2013).
78. 3 adenosine receptor knock-out mice. Physiol. Behav. 95, 668-676 (2008).
79. 3 receptors regulate heart rate, motor activity and body temperature. Acta Physiol. 199, 221-230 (2010).
80. 2B receptors. J. Exp. Med. 198, 783-796 (2003).
81. Thompson, L. F. et al. Crucial role for ecto-5′-nucleotidase (CD73) in vascular leakage during hypoxia. J. Exp. Med. 200, 1395-1405 (2004).
82. 2A receptors. Annu. Rev. Immunol. 22, 657-682 (2004).
83. Gomes, C. V., Kaster, M. P., Tome, A. R., Agostinho, P. M. & Cunha, R. A. Adenosine receptors and brain diseases: neuroprotection and neurodegeneration. Biochim. Biophys. Acta 1808, 1380-1399 (2011).
84. Boison, D. Adenosine dysfunction in epilepsy. Glia 60, 1234-1243 (2012).
85. Linden, J. Regulation of leukocyte function by adenosine receptors. Adv. Pharmacol. 61, 95-114 (2011).
86. Synnestvedt, K. et al. Ecto-5′-nucleotidase (CD73) regulation by hypoxia-inducible factor-1 mediates permeability changes in intestinal epithelia. J. Clin. Invest. 110, 993-1002 (2002).
87. Zetterstrom, T. et al. Purine levels in the intact rat brain. Studies with an implanted perfused hollow fibre. Neurosci. Lett. 29, 111-115 (1982).
88. 2A receptors in ischemia. Ann. NY Acad. Sci. 939, 74-84 (2001).
89. Andine, P., Rudolphi, K. A., Fredholm, B. B. & Hagberg, H. Effect of propentofylline (HWA 285) on extracellular purines and excitatory amino acids in CA1 of rat hippocampus during transient ischaemia. Br. J. Pharmacol. 100, 814-818 (1990).
90. Dux, E., Fastbom, J., Ungerstedt, U., Rudolphi, K. & Fredholm, B. B. Protective effect of adenosine and a novel xanthine derivative propentofylline on the cell damage after bilateral carotid occlusion in the gerbil hippocampus. Brain Res. 516, 248-256 (1990).
91. 1 receptor. Proc. Natl Acad. Sci. USA 98, 9407-9412 (2001).
92. Eckle, T., Koeppen, M. & Eltzschig, H. K. Role of extracellular adenosine in acute lung injury. Physiology 24, 298-306 (2009).
93. 2A receptor is a unique angiogenic target of HIF-2α in pulmonary endothelial cells. Proc. Natl Acad. Sci. USA 106, 10684-10689 (2009).
94. Eckle, T., Kohler, D., Lehmann, R., El Kasmi, K. C. & Eltzschig, H. K. Hypoxia-inducible factor-1 is central to cardioprotection: a new paradigm for ischemic preconditioning. Circulation 118, 166-175 (2008).
95. 2B receptor in hypoxia. FASEB J. 20, 2242-2250 (2006).
96. Eltzschig, H. K. et al. Central role of Sp1-regulated CD39 in hypoxia/ischemia protection. Blood 113, 224-232 (2009).
97. Hart, M. L., Gorzolla, I. C., Schittenhelm, J., Robson, S. C. & Eltzschig, H. K. SP1-dependent induction of CD39 facilitates hepatic ischemic preconditioning. J. Immunol. 184, 4017-4024 (2010).
98. Kohler, D. et al. CD39/ectonucleoside triphosphate diphosphohydrolase 1 provides myocardial protection during cardiac ischemia/reperfusion injury. Circulation 116, 1784-1794 (2007).
99. Reutershan, J. et al. Adenosine and inflammation: CD39 and CD73 are critical mediators in LPS-induced PMN trafficking into the lungs. FASEB J. 23, 473-482 (2009).
100. Hart, M. L. et al. Extracellular adenosine production by ecto-5′-nucleotidase protects during murine hepatic ischemic preconditioning. Gastroenterology 135, 1739-1750.e3 (2008).
101. 2B adenosine receptors protect against sepsis-induced mortality by dampening excessive inflammation. J. Immunol. 185, 542-550 (2010).
102. 2A receptor activation reduces hepatic ischemia reperfusion injury by inhibiting CD1d-dependent NKT cell activation. J. Exp. Med. 203, 2639-2648 (2006).
103. 2A adenosine receptors on bone marrow-derived cells protect liver from ischemia-reperfusion injury. J. Immunol. 174, 5040-5046 (2005).
104. Enjyoji, K. et al. Targeted disruption of CD39/ATP diphosphohydrolase results in disordered hemostasis and thromboregulation. Nature Med. 5, 1010-1017 (1999).
105. Marcus, A. J. et al. Metabolic control of excessive extracellular nucleotide accumulation by CD39/ecto-nucleotidase-1: implications for ischemic vascular diseases. J. Pharmacol. Exp. Ther. 305, 9-16 (2003).
106. Eckle, T. et al. Identification of ectonucleotidases CD39 and CD73 in innate protection during acute lung injury. J. Immunol. 178, 8127-8137 (2007).
107. Grenz, A. et al. Contribution of E-NTPDase1 (CD39) to renal protection from ischemia-reperfusion injury. FASEB J. 21, 2863-2873 (2007).
108. Grenz, A. et al. Protective role of ecto-5'-nucleotidase (CD73) in renal ischemia. J. Am. Soc. Nephrol. 18, 833-845 (2007).
109. Hasko, G. et al. Ecto-5'-nucleotidase (CD73) decreases mortality and organ injury in sepsis. J. Immunol. 187, 4256-4267 (2011).
110. 2A receptors in C6 glioma cells during hypoxia: involvement of endogenous adenosine. J. Neurochem. 105, 2315-2329 (2008).
111. Angelatou, F. et al. Upregulation of A1 adenosine receptors in human temporal lobe epilepsy: a quantitative autoradiographic study. Neurosci. Lett. 163, 11-14 (1993).
112. Biber, K. et al. Interleukin-6 upregulates neuronal adenosine A1 receptors: implications for neuromodulation and neuroprotection. Neuropsychopharmacology 33, 2237-2250 (2008).
113. Jin, D. et al. CD73 on tumor cells impairs antitumor T-cell responses: a novel mechanism of tumor-induced immune suppression. Cancer Res. 70, 2245-2255 (2010).
114. + regulatory T cells promotes hepatic metastatic tumor growth in mice. Gastroenterology 139, 1030-1040 (2010).
115. 2A adenosine receptor protects tumors from antitumor T cells. Proc. Natl Acad. Sci. USA 103, 13132-13137 (2006).
116. Popoli, P. et al. Blockade of striatal adenosine A2A receptor reduces, through a presynaptic mechanism, quinolinic acid-induced excitotoxicity: possible relevance to neuroprotective interventions in neurodegenerative diseases of the striatum. J. Neurosci. 22, 1967-1975 (2002).
117. 2A receptor regulation of neuroinflammation and traumatic brain injury. J. Neurosci. 30, 5802-5810 (2010).
118. 2A receptors attenuates acute traumatic brain injury in the mouse cortical impact model. Exp. Neurol. 215, 69-76 (2009).
119. 2A adenosine receptor inactivation in a model of Parkinson's disease. J. Neurosci. 21, RC143 (2001).
120. 2A receptor blockade prevents synaptotoxicity and memory dysfunction caused by ß-amyloid peptides via p38 mitogen-activated protein kinase pathway. J. Neurosci. 29, 14741-14751 (2009).
121. 2A antagonists. J. Neurosci. 23, 5361-5369 (2003).
122. Chou, S. Y. et al. CGS21680 attenuates symptoms of Huntington's disease in a transgenic mouse model. J. Neurochem. 93, 310-320 (2005).
123. 2A receptor on non-bone marrow-derived cells. Neuroscience 141, 2029-2039 (2006).
124. 3 adenosine receptor agonist CF102 induces apoptosis of hepatocellular carcinoma via de-regulation of the Wnt and NF-KB signal transduction pathways. Int. J. Oncol. 33, 287-295 (2008).
125. Deaglio, S. et al. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J. Exp. Med. 204, 1257-1265 (2007).
126. Eltzschig, H. K. et al. HIF-1-dependent repression of equilibrative nucleoside transporter (ENT) in hypoxia. J. Exp. Med. 202, 1493-1505 (2005).
127. Loffler, M., Morote-Garcia, J. C, Eltzschig, S. A., Coe, I. R. & Eltzschig, H. K. Physiological roles of vascular nucleoside transporters. Arterioscler Thromb. Vasc. Biol. 27, 1004-1013 (2007).
128. Morote-Garcia, J. C., Rosenberger, P., Nivillac, N. M., Coe, I. R. & Eltzschig, H. K. Hypoxia-inducible factor-dependent repression of equilibrative nucleoside transporter 2 attenuates mucosal inflammation during intestinal hypoxia. Gastroenterology 136, 607-618 (2009).
129. Sitkovsky, M. V. Damage control by hypoxia-inhibited AK. Blood 111, 5424-5425 (2008).
130. Morote-Garcia, J. C., Rosenberger, P., Kuhlicke, J. & Eltzschig, H. K. HIF-1-dependent repression of adenosine kinase attenuates hypoxia-induced vascular leak. Blood 111, 5571-5580 (2008).
131. 2A receptors in human monocytic THP-1 cells. J. Immunol. 167, 4026-4032 (2001).
132. Haschemi, A. et al. Cross-regulation of carbon monoxide and the adenosine A2a receptor in macrophages. J. Immunol. 178, 5921-5929 (2007).
133. Zhang, Y., Palmblad, J. & Fredholm, B. B. Biphasic effect of ATP on neutrophil functions mediated by P2U and adenosine A2A receptors. Biochem. Pharmacol. 51, 957-965 (1996).
134. Colgan, S. P. & Eltzschig, H. K. Adenosine and hypoxia-inducible factor signaling in intestinal injury and recovery. Annu. Rev. Physiol. 74, 153-175 (2011).
135. Fredholm, B. B. Adenosine receptors as drug targets. Exp. Cell Res. 316, 1284-1288 (2010).
136. 1 adenosine receptor ligands. Curr. Top. Med. Chem. 3, 369-385 (2003).
137. 2A receptor as an attractive target for Parkinson's disease treatment. Drug News Perspect. 16, 597-604 (2003).
138. 2A antagonists, and Parkinson's disease. Parkinsonism Relat. Disord. 15, 406-413 (2009).
139. Hauser, R. A. et al. Preladenant in patients with Parkinson's disease and motor fluctuations: a phase 2, double-blind, randomised trial. Lancet Neurol. 10, 221-229 (2011).
140. Guttman, M. Efficacy of istradefylline in Parkinson's diease patients treated with levodopa with motor response complications: results of the KW-6002 US-018 study. Mov. Disord. 21 (Suppl. 15), 585 (2006).
141. Meissner, W. G. et al. Priorities in Parkinson's disease research. Nature Rev. Drug Discov. 10, 377-393 (2011).
142. Vallon, V., Muhlbauer, B. & Osswald, H. Adenosine and kidney function. Physiol. Rev. 86, 901-940 (2006).
143. 1 receptor antagonist rolofylline in patients with acute heart failure and renal impairment. J. Card. Fail. 14, 631-640 (2008).
144. 1 receptor antagonist rolofylline for patients hospitalized with acute decompensated heart failure and volume overload to assess treatment effect on congestion and renal function). J. Am. Coll. Cardiol. 57, 1899-1907 (2011).
145. Gessi, S. et al. Adenosine receptor targeting in health and disease. Expert Opin. Investig. Drugs 20, 1591-1609 (2011).
146. 3 adenosine receptor as a target to treat rheumatoid arthritis: data from a phase II clinical trial. J. Rheumatol. 35, 41-48 (2008).
147. Avni, I. et al. Treatment of dry eye syndrome with orally administered CF101: data from a phase 2 clinical trial. Ophthalmology 117, 1287-1293 (2010).
148. + T cells reduces melanoma growth in mice. PLoS ONE 7, e45401 (2012).
149. 3 adenosine receptor activation. FASEB J. 26, 1855-1865 (2012).
150. 3 adenosine receptors in human neutrophils and promyelocytic HL60 cells: a pharmacological and biochemical study. Mol. Pharmacol. 61, 415-424 (2002).
151. 3 adenosine receptor modulators: pharmacological activities and therapeutic implications. J. Med. Chem. 55, 5676-5703 (2012).
152. 2A receptors induced on iNKT and NK cells reduce pulmonary inflammation and injury in mice with sickle cell disease. Blood 116, 5010-5020 (2010).
153. Zhang, Y. et al. Detrimental effects of adenosine signaling in sickle cell disease. Nature Med. 17, 79-86 (2011).
154. Field, J. J., Nathan, D. G. & Linden, J. Targeting iNKT cells for the treatment of sickle cell disease. Clin. Immunol. 140, 177-183 (2011).
155. Gladwin, M. T. Adenosine receptor crossroads in sickle cell disease. Nature Med. 17, 38-40 (2011).
156. Schmitt, L. I., Sims, R. E., Dale, N. & Haydon, P. G. Wakefulness affects synaptic and network activity by increasing extracellular astrocyte-derived adenosine. J. Neurosci. 32, 4417-4425 (2012).
157. Lovatt, D. et al. Neuronal adenosine release, and not astrocytic ATP release, mediates feedback inhibition of excitatory activity. Proc. Natl Acad. Sci. USA 109, 5913-5914 (2012).
158. Ramlackhansingh, A. F. et al. Adenosine 2A receptor availability in dyskinetic and nondyskinetic patients with Parkinson disease. Neurology 76, 1811-1816 (2011).
159. CTMSX PET in the striata of Parkinson's disease patients. PLoS ONE 6, e17338 (2011).
160. Cha, J. H. et al. Altered brain neurotransmitter receptors in transgenic mice expressing a portion of an abnormal human huntington disease gene. Proc. Natl Acad. Sci. USA 95, 6480-6485 (1998).
161. 2A receptors in Huntington's disease. Prog. Neurobiol. 81, 331-348 (2007).
162. Thiel, M. et al. Oxygenation inhibits the physiological tissue-protecting mechanism and thereby exacerbates acute inflammatory lung injury. PLoS Biol. 3, e174 (2005).
163. 2B adenosine receptor during gastrointestinal ischemia and inflammation. Expert Opin. Ther. Targets 13, 1267-1277 (2009).
164. 2A adenosine receptors during reperfusion: inhibition of chemokine induction. Am. J. Physiol. Gastrointest. Liver Physiol. 286, G285-G293 (2004).
165. Zhou, Y., Schneider, D. J. & Blackburn, M. R. Adenosine signaling and the regulation of chronic lung disease. Pharmacol. Ther. 123, 105-116 (2009).
166. Chunn, J. L. et al. Adenosine-dependent pulmonary fibrosis in adenosine deaminase-deficient mice. J. Immunol. 175, 1937-1946 (2005).
167. 2B receptor signaling in adenosine-dependent pulmonary inflammation and injury. J. Clin. Invest. 116, 1-10 (2006).
168. Peng, Z. et al. Adenosine signaling contributes to ethanol-induced fatty liver in mice. J. Clin. Invest. 119, 582-594 (2009).
169. 2A receptors in diffuse dermal fibrosis: pathogenic role in human dermal fibroblasts and in a murine model of scleroderma. Arthritis Rheum. 54, 2632-2642 (2006).
170. 2B adenosine receptor signaling. FASEB J. 24, 740-749 (2010).
171. 2B adenosine receptor signaling. J. Clin. Invest. 118, 1491-1501 (2008).
172. Volmer, J. B., Thompson, L. F. & Blackburn, M. R. Ecto-5'-nucleotidase (CD73)-mediated adenosine production is tissue protective in a model of bleomycin-induced lung injury. J. Immunol. 176, 4449-4458 (2006).
173. 2B adenosine receptor. J. Immunol. 182, 8037-8046 (2009).
174. 2B adenosine receptor signaling in adenosine-dependent pulmonary inflammation and injury. J. Clin. Invest. 116, 2173-2182 (2006).
175. 2B adenosine receptor in acute and chronic stages of bleomycin-induced lung injury. J. Immunol. 186, 1097-1106 (2011).
176. 2A adenosine receptor activation improves survival in mouse models of endotoxemia and sepsis. J. Infect. Dis. 189, 1897-1904 (2004).
177. 2A receptor inactivation increases survival in polymicrobial sepsis. J. Immunol. 176, 5616-5626 (2006).
178. 2A adenosine receptors and C/EBPß are crucially required for IL-10 production by macrophages exposed to Escherichia coli. Blood 110, 2685-2695 (2007).
179. 2A receptors play a role in the pathogenesis of hepatic cirrhosis. Br. J. Pharmacol. 148, 1144-1155 (2006).
180. 2A receptor agonist CGS21680 in the striatum of Huntington's disease versus wild-type mice. Neurosci. Lett. 417, 78-83 (2007).
181. Obrenovitch, T. P. & Urenjak, J. Altered glutamatergic transmission in neurological disorders: from high extracellular glutamate to excessive synaptic efficacy Prog. Neurobiol. 51, 39-87 (1997).
182. Haydon, P. G. & Carmignoto, G. Astrocyte control of synaptic transmission and neurovascular coupling. Physiol. Rev. 86, 1009-1031 (2006).
183. Jacobson, K. A., von Lubitz, D. K., Daly, J. W. & Fredholm, B. B. Adenosine receptor ligands: differences with acute versus chronic treatment. Trends Pharmacol. Sci. 17, 108-113 (1996).
184. Fredholm, B. B., Battig, K., Holmen, J., Nehlig, A. & Zvartau, E. E. Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. Pharmacol. Rev. 51, 83-133 (1999).
185. de Mendonca, A., Sebastiao, A. M. & Ribeiro, J. A. Adenosine: does it have a neuroprotective role after all? Brain Res. Brain Res. Rev. 33, 258-274 (2000).
186. Von Lubitz, D. K. et al. Chronic administration of selective adenosine A1 receptor agonist or antagonist in cerebral ischemia. Eur. J. Pharmacol. 256, 161-167 (1994).
187. Von Lubitz, D. K. et al. Reduction of postischemic brain damage and memory deficits following treatment with the selective adenosine A1 receptor agonist. Eur. J. Pharmacol. 302, 43-48 (1996).
188. 2A receptor interacts with the actin-binding protein a-actinin. J. Biol. Chem. 278, 37545-37552 (2003).
189. Chern, Y., Lai, H. L, Fong, J. C. & Liang, Y. Multiple mechanisms for desensitization of A2a adenosine receptor-mediated cAMP elevation in rat pheochromocytoma PC12 cells. Mol. Pharmacol. 44, 950-958 (1993).
190. 2A receptor antagonist. Eur. J. Pharmacol. 406, 345-354 (2000).
191. 2A receptor antagonist SCH 58261 do not develop tolerance after repeated treatments in 6-hydroxydopamine-lesioned rats. Synapse 39, 233-238 (2001).
192. 2A receptors in amphetamine sensitization. Neuropsychopharmacology 30, 891-900 (2005).
193. 2A receptor antagonists exert motor and neuroprotective effects by distinct cellular mechanisms. Ann. Neurol. 63, 338-346 (2008).
194. 2A receptor knock-outs. J. Neurosci. 28, 2970-2975 (2008).
195. 1 receptor in adult mice using an adeno-associated viral vector. J. Neurosci. 23, 5762-5770 (2003).
196. Adamantidis, A. R., Zhang, F., Aravanis, A. M., Deisseroth, K. & de Lecea, L. Neural substrates of awakening probed with optogenetic control of hypocretin neurons. Nature 450, 420-424 (2007).
197. Deisseroth, K. et al. Next-generation optical technologies for illuminating genetically targeted brain circuits. J. Neurosci. 26, 10380-10386 (2006).
198. - channel. Neuron 54, 35-49 (2007).
199. Alexander, G. M. et al. Remote control of neuronal activity in transgenic mice expressing evolved G protein-coupled receptors. Neuron 63, 27-39 (2009).
200. Nawaratne, V. et al. New insights into the function of M4 muscarinic acetylcholine receptors gained using a novel allosteric modulator and a DREADD (designer receptor exclusively activated by a designer drug). Mol. Pharmacol. 74, 1119-1131 (2008).
201. 2A knockout mice. Stroke 34, 739-744 (2003).
202. Burnstock, G., Fredholm, B. B. & Verkhratsky, A. Adenosine and ATP receptors in the brain. Curr. Top. Med. Chem. 11, 973-1011 (2011).
203. Boison, D., Chen, J. F. & Fredholm, B. B. Adenosine signaling and function in glial cells. Cell Death Differ. 17, 1071-1082 (2010).
204. 1 adenosine receptors mediate hypoxia-induced ventriculomegaly. Proc. Natl Acad. Sci. USA 100, 11718-11722 (2003).
205. Chabre, M. & le Maire, M. Monomeric G-protein-coupled receptor as a functional unit. Biochemistry 44, 9395-9403 (2005).
206. Whorton, M. R. et al. A monomeric G protein-coupled receptor isolated in a high-density lipoprotein particle efficiently activates its G protein. Proc. Natl Acad. Sci. USA 104, 7682-7687 (2007).
207. Ferre, S. et al. Building a new conceptual framework for receptor heteromers. Nature Chem. Biol. 5, 131-134 (2009).
208. 2A receptors in the rat striatum. Neuropharmacology 61, 967-974 (2011).
209. 2A adenosine receptor antagonists in the therapy of Parkinson's disease. Pharmacol. Ther. 132, 280-299 (2011).
210. 2B receptor. J. Biol. Chem. 285, 39271-39288 (2010).
211. 2A-dopamine D2 receptor-receptor heteromerization: qualitative and quantitative assessment by fluorescence and bioluminescence energy transfer. J. Biol. Chem. 278, 46741-46749 (2003).
212. 2A receptor heteromers. J. Neurosci. 26, 2080-2087 (2006).
213. 2A and glutamate mGlu5 receptors: implications for striatal neuronal function. Proc. Natl Acad. Sci. USA 99, 11940-11945 (2002).
214. Pin, J. P. et al. International Union of Basic and Clinical Pharmacology. LXVII. Recommendations for the recognition and nomenclature of G proteincoupled receptor heteromultimers. Pharmacol. Rev. 59, 5-13 (2007).
215. 2A adenosine receptor genes show similarities to mice given long-term caffeine. J. Appl. Physiol. 106, 631-639 (2009).
216. Ascherio, A. et al. Prospective study of caffeine consumption and risk of Parkinson's disease in men and women. Ann. Neurol. 50, 56-63 (2001).
217. Ross, G. W. et al. Association of coffee and caffeine intake with the risk of Parkinson disease. JAMA 283, 2674-2679 (2000).
218. Lindsay, J. et al. Risk factors for Alzheimer's disease: a prospective analysis from the Canadian Study of Health and Aging. Am. J. Epidemiol. 156, 445-453 (2002).
219. van Boxtel, M. P., Schmitt, J. A., Bosma, H. & Jolles, J. The effects of habitual caffeine use on cognitive change: a longitudinal perspective. Pharmacol. Biochem. Behav. 75, 921-927 (2003).
220. Ritchie, K. et al. The neuro-protective effects of caffeine: a prospective population study (the Three City Study). Neurology 69, 536-545 (2007).
221. Higdon, J. V. & Frei, B. Coffee and health: a review of recent human research. Crit. Rev. Food Sci. Nutr. 46, 101-123 (2006).
222. Salazar-Martinez, E. et al. Coffee consumption and risk for type 2 diabetes mellitus. Ann. Intern. Med. 140, 1-8 (2004).
223. Schmidt, B. et al. Caffeine therapy for apnea of prematurity. N. Engl. J. Med. 354, 2112-2121 (2006).
224. Schmidt, B. et al. Long-term effects of caffeine therapy for apnea of prematurity. N. Engl. J. Med. 357, 1893-1902 (2007).
225. Saaksjarvi, K. et al. Prospective study of coffee consumption and risk of Parkinson's disease. Eur. J. Clin. Nutr. 62, 908-915 (2008).
226. Powers, K. M. et al. Combined effects of smoking, coffee, and NSAIDs on Parkinson's disease risk. Mov. Disord. 23, 88-95 (2008).
227. Fernandez, H. H. et al. Istradefylline as monotherapy for Parkinson disease: results of the 6002-US-051 trial. Parkinsonism Relat. Disord. 16, 16-20 (2010).
228. Chen, J. F. et al. What knock-out animals tell us about the effects of caffeine. J. Alzheimers Dis. 20 (Suppl. 1), 17-24 (2010).
229. Tejani, F. H., Thompson, R. C., Iskandrian, A. E., McNutt, B. E. & Franks, B. Effect of caffeine on SPECT myocardial perfusion imaging during regadenoson pharmacologic stress: rationale and design of a prospective, randomized, multicenter study. J. Nucl. Cardiol. 18, 73-81 (2011).
230. Cabalag, M. S. et al. Recent caffeine ingestion reduces adenosine efficacy in the treatment of paroxysmal supraventricular tachycardia. Acad. Emerg. Med. 17, 44-49 (2010).
231. Pourcher, E. et al. Istradefylline for Parkinson's disease patients experiencing motor fluctuations: results of the KW-6002-US-018 study. Parkinsonism Relat. Disord. 18, 178-184 (2012).
232. Factor, S. et al. A long-term study of istradefylline in subjects with fluctuating Parkinson's disease. Parkinsonism Relat. Disord. 16, 423-426 (2010).
233. Hauser, R. A. et al. Study of istradefylline in patients with Parkinson's disease on levodopa with motor fluctuations. Mov. Disord. 23, 2177-2185 (2008).
234. Rao, N. et al. A study of the pharmacokinetic interaction of istradefylline, a novel therapeutic for Parkinson's disease, and atorvastatin. J. Clin. Pharmacol. 48, 1092-1098 (2008).
235. Stacy, M. et al. A 12-week, placebo-controlled study (6002-US-006) of istradefylline in Parkinson disease. Neurology 70, 2233-2240 (2008).
236. 2A receptor antagonist istradefylline (KW-6002) reduces "off" time in Parkinson's disease: a double-blind, randomized, multicenter clinical trial (6002-US-005). Ann. Neurol. 63, 295-302 (2008).
237. Robak, T. & Robak, P. Purine nucleoside analogs in the treatment of rarer chronic lymphoid leukemias. Curr. Pharm. Des. 18, 3373-3388 (2012).
238. 1 receptor binding and function by 2-amino-3-benzoylthiophenes. Mol. Pharmacol. 38, 939-949 (1990).
239. Katritch, V., Cherezov, V. & Stevens, R. C. Diversity and modularity of G protein-coupled receptor structures. Trends Pharmacol. Sci. 33, 17-27 (2012).
240. 2A receptor antagonism. J. Biol. Chem. 277, 36040-36044 (2002).
241. Huang, N. K. et al. A new drug design targeting the adenosinergic system for Huntington's disease. PLoS ONE 6, e20934 (2011).
242. 2A receptor agonists activated by ecto-5′- nucleotidase. J. Med. Chem. 52, 7669-7677 (2009).
243. 2A receptors on immune cells by a CD73-dependent prodrug suppresses joint inflammation in experimental rheumatoid arthritis. Sci. Transl. Med. 4, 146ra108 (2012).
244. 2A signaling. Prog. Neurobiol. 83, 263-276 (2007).
245. Allen, J. A. et al. Discovery of β-arrestin-biased dopamine D2 ligands for probing signal transduction pathways essential for antipsychotic efficacy. Proc. Natl Acad. Sci. USA 108, 18488-18493 (2011).
246. 1 receptor ligands? Purinergic Signal. 7, 171-192 (2012).
247. 2A receptor structures reveal common features of GPCR activation. Nature 474, 521-525 (2011).
248. 2A adenosine receptor. Science 332, 322-327 (2011).
249. 2A adenosine receptor bound to an antagonist. Science 322, 1211-1217 (2008).
250. Liu, W. et al. Structural basis for allosteric regulation of GPCRs by sodium ions. Science 337, 232-236 (2012).
251. Kobilka, B. K. Structural insights into adrenergic receptor function and pharmacology. Trends Pharmacol. Sci. 32, 213-218 (2011).
252. 1 receptor antagonists in clinical research and development. Kidney Int. 78, 438-445 (2010).
253. Bennet, D. W. & Drury, A. N. Further observations relating to the physiological activity of adenine compounds. J. Physiol. 72, 288-320 (1931).
254. Drury, A. N. & Szent-Gyorgyi, A. The physiological activity of adenine compounds with especial reference to their action upon the mammalian heart. J. Physiol. 68, 213-237 (1929).
255. Stoner, H. B. & Green, H. N. Experimental limb ischaemia in man with especial reference to the role of adenosine triphosphate. Clin. Sci. 5, 159-175 (1945).
256. Massion, W. H. Value of high energy compounds in the treatment of shock. Am. J. Surg. 110, 342-347 (1965).
257. Yang, D. et al. A new role for the A2b adenosine receptor in regulating platelet function. J. Thromb. Haemost. 8, 817-827 (2010).
258. Berne, R. M. Cardiac nucleotides in hypoxia: possible role in regulation of coronary blood flow. Am. J. Physiol. 204, 317-322 (1963).
259. Gerlach, E., Deuticke, B. & Dreisbach, R. H. Der Nucleotid-Abbau im Herzmuskel bei Sauerstoffmangel und seine mögliche Bedeutung für die Coronardurchblutung. Naturwissenschaften 50, 228-229 (in German) (1963).
260. Mustafa, S. J., Berne, R. M. & Rubio, R. Adenosine metabolism in cultured chick-embryo heart cells. Am. J. Physiol. 228, 1474-1478 (1975).
261. Duncker, D. J. & Merkus, D. Exercise hyperaemia in the heart: the search for the dilator mechanism. J. Physiol. 583, 847-854 (2007).
262. 1 adenosine receptor expression on protection with ischemic preconditioning. Am. J. Physiol. Heart Circ. Physiol. 290, H1469-H1473 (2006).
263. Yang, A., Palmer, A. A. & de Wit, H. Genetics of caffeine consumption and responses to caffeine. Psychopharmacology 211, 245-257 (2010).
264. Retey, J. V. et al. A functional genetic variation of adenosine deaminase affects the duration and intensity of deep sleep in humans. Proc. Natl Acad. Sci. USA 102, 15676-15681 (2005).
265. Landolt, H. P. Sleep homeostasis: a role for adenosine in humans? Biochem. Pharmacol. 75, 2070-2079 (2008).
266. 2A receptor gene (ADORA2A) contributes to individual sensitivity to caffeine effects on sleep. Clin. Pharmacol. Ther. 81, 692-698 (2007).
267. Childs, E. et al. Association between ADORA2A and DRD2 polymorphisms and caffeine-induced anxiety. Neuropsychopharmacology 33, 2791-2800 (2008).
268. Domschke, K. et al. ADORA2A gene variation, caffeine, and emotional processing: a multi-level interaction on startle reflex. Neuropsychopharmacology 37, 759-769 (2012).
269. Alsene, K., Deckert, J., Sand, P. & de Wit, H. Association between A2a receptor gene polymorphisms and caffeine-induced anxiety. Neuropsychopharmacology 28, 1694-1702 (2003).
270. Taherzadeh-Fard, E., Saft, C., Wieczorek, S., Epplen, J. T. & Arning, L. Age at onset in Huntington's disease: replication study on the associations of ADORA2A, HAP1 and OGG1. Neurogenetics 11, 435-439 (2010).
271. Popat, R. A. et al. Coffee, ADORA2A, and CYP1A2: the caffeine connection in Parkinson's disease. Eur. J. Neurol. 18, 756-765 (2011).
272. Amin, N. et al. Genome-wide association analysis of coffee drinking suggests association with CYP1A1/CYP1A2 and NRCAM. Mol. Psychiatry 17, 1116-1129 (2011).
273. Hamza, T. H. et al. Genome-wide gene-environment study identifies glutamate receptor gene GRIN2A as a Parkinson's disease modifier gene via interaction with coffee. PLoS Genet. 7, e1002237 (2011).
274. Tantry, U. S. et al. First analysis of the relation between CYP2C19 genotype and pharmacodynamics in patients treated with ticagrelor versus clopidogrel: the ONSET/OFFSET and RESPOND genotype studies. Circ. Cardiovasc. Genet. 3, 556-566 (2010).
275. 1 adenosine receptor agonists and their potential therapeutic applications. Expert Opin. Investig. Drugs 17, 1901-1910 (2008).
276. 2A receptor antagonists for Parkinson's disease. Expert Opin. Investig. Drugs 18, 1619-1631 (2009).
277. 1 receptor-deficient mice. Am. J. Physiol. Regul. Integr. Comp. Physiol. 281, R1362-R1367 (2001).
278. 1 adenosine receptors in regulation of vascular tone. Am. J. Physiol. Heart Circ. Physiol. 288, H1411-H1416 (2005).
279. 1 receptors and vascular reactivity. Acta Physiol. 199, 211-220 (2010).
280. 1 adenosine receptors and neural pathways in adenosine-induced bronchoconstriction in mice. Am. J. Physiol. Lung Cell. Mol. Physiol. 293, L25-L32 (2007).
281. 1 receptor deficiency causes increased insulin and glucagon secretion in mice. Biochem. Pharmacol. 74, 1628-1635 (2007).
282. 1 receptors. Acta Physiol. 190, 63-75 (2007).
283. 1 receptor-knockout mice. Arthritis Rheum. 62, 534-541 (2010).
284. 1 receptor. J. Sleep Res. 12, 283-290 (2003).
285. 1 receptors and promotes non-rapid eye movement sleep. Proc. Natl Acad. Sci. USA 105, 19992-19997 (2008).
286. 1 receptor. Pain 113, 395-404 (2005).
287. Schulte, G. et al. Adenosine A receptors are necessary for protection of the murine heart by remote, delayed adaptation to ischaemia. Acta Physiol. Scand. 182, 133-143 (2004).
288. + T cells. J. Immunol. 174, 1073-1080 (2005).
289. Carman, A. J., Mills, J. H., Krenz, A., Kim, D. G. & Bynoe, M. S. Adenosine receptor signaling modulates permeability of the blood-brain barrier. J. Neurosci. 31, 13272-13280 (2011).
290. Chen, X., Lan, X., Roche, I., Liu, R. & Geiger, J. D. Caffeine protects against MPTP-induced blood-brain barrier dysfunction in mouse striatum. J. Neurochem. 107, 1147-1157 (2008).
291. Chen, X., Gawryluk, J. W., Wagener, J. F., Ghribi, O. & Geiger, J. D. Caffeine blocks disruption of blood brain barrier in a rabbit model of Alzheimer's disease. J. Neuroinflamm. 5, 12 (2008).
292. 2B receptors. Am. J. Physiol. Heart Circ. Physiol. 282, H437-H444 (2002).
293. 2A receptors. Am. J. Pathol. 160, 2009-2018 (2002).
294. 3 receptors on mast cells. J. Clin. Invest. 105, 361-367 (2000).
295. 3 receptors on mast cells. J. Allergy Clin. Immunol. 122, 107-113.e7 (2008).
296. 2AR agonist attenuate acute kidney injury. J. Clin. Invest. 122, 3931-3942 (2012).
297. 2A receptor agonist regadenoson. Blood 1 Feb 2013 (doi:10.1182/blood-2012-11-465963).